Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.
A benign tumor containing vascular, adipose, and muscle elements. It occurs most often in the kidney with smooth muscle elements (angiolipoleiomyoma) in association with tuberous sclerosis. (Dorland, 27th ed)
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
A benign tumor derived from striated muscle. It is extremely rare, generally occurring in the tongue, neck muscles, larynx, uvula, nasal cavity, axilla, vulva, and heart. These tumors are treated by simple excision. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1354)
A disease characterized by the progressive invasion of SMOOTH MUSCLE CELLS into the LYMPHATIC VESSELS, and the BLOOD VESSELS. The majority of the cases occur in the LUNGS of women of child-bearing age, eventually blocking the flow of air, blood, and lymph. The common symptom is shortness of breath (DYSPNEA).
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve.
A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that SIROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.
Facial neoplasms are abnormal growths or tumors that develop in the facial region, which can be benign or malignant, originating from various cell types including epithelial, glandular, connective tissue, and neural crest cells.
A benign neoplasm of fibrous tissue in which there are numerous small and large, frequently dilated, vascular channels. (Stedman, 25th ed)
A focal malformation resembling a neoplasm, composed of an overgrowth of mature cells and tissues that normally occur in the affected area.
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
Abnormalities in the development of the CEREBRAL CORTEX. These include malformations arising from abnormal neuronal and glial CELL PROLIFERATION or APOPTOSIS (Group I); abnormal neuronal migration (Group II); and abnormal establishment of cortical organization (Group III). Many INBORN METABOLIC BRAIN DISORDERS affecting CNS formation are often associated with cortical malformations. They are common causes of EPILEPSY and developmental delay.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
Macromolecular complexes formed from the association of defined protein subunits.
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
Sebaceous gland neoplasms are uncommon cutaneous tumors that originate from the sebaceous glands, which can be benign (e.g., seborrheic keratosis, syringoma, trichofolliculoma) or malignant (e.g., sebaceous carcinoma, sebaceomatosis, mucoepidermoid carcinoma).
An epileptic syndrome characterized by the triad of infantile spasms, hypsarrhythmia, and arrest of psychomotor development at seizure onset. The majority present between 3-12 months of age, with spasms consisting of combinations of brief flexor or extensor movements of the head, trunk, and limbs. The condition is divided into two forms: cryptogenic (idiopathic) and symptomatic (secondary to a known disease process such as intrauterine infections; nervous system abnormalities; BRAIN DISEASES, METABOLIC, INBORN; prematurity; perinatal asphyxia; TUBEROUS SCLEROSIS; etc.). (From Menkes, Textbook of Child Neurology, 5th ed, pp744-8)
A class of monomeric, low molecular weight (20-25 kDa) GTP-binding proteins that regulate a variety of intracellular processes. The GTP bound form of the protein is active and limited by its inherent GTPase activity, which is controlled by an array of GTPase activators, GDP dissociation inhibitors, and guanine nucleotide exchange factors. This enzyme was formerly listed as EC 3.6.1.47
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
Tumors or cancers of the KIDNEY.
Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release.
A family of protein serine/threonine kinases which act as intracellular signalling intermediates. Ribosomal protein S6 kinases are activated through phosphorylation in response to a variety of HORMONES and INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS. Phosphorylation of RIBOSOMAL PROTEIN S6 by enzymes in this class results in increased expression of 5' top MRNAs. Although specific for RIBOSOMAL PROTEIN S6 members of this class of kinases can act on a number of substrates within the cell. The immunosuppressant SIROLIMUS inhibits the activation of ribosomal protein S6 kinases.
A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
A benign tumor of fibrous or fully developed connective tissue.
Pigmentation disorders are conditions that affect the production or distribution of melanin, the pigment responsible for skin, hair, and eye color, leading to changes in the color of these bodily features.
Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
A congenital abnormality in which the occipitofrontal circumference is greater than two standard deviations above the mean for a given age. It is associated with HYDROCEPHALUS; SUBDURAL EFFUSION; ARACHNOID CYSTS; or is part of a genetic condition (e.g., ALEXANDER DISEASE; SOTOS SYNDROME).
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
A condition caused by a deficiency or a loss of melanin pigmentation in the epidermis, also known as hypomelanosis. Hypopigmentation can be localized or generalized, and may result from genetic defects, trauma, inflammation, or infections.
A family of enzymes that catalyze the conversion of ATP and a protein to ADP and a phosphoprotein.
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or "seizure disorder."
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.
An analogue of GAMMA-AMINOBUTYRIC ACID. It is an irreversible inhibitor of 4-AMINOBUTYRATE TRANSAMINASE, the enzyme responsible for the catabolism of GAMMA-AMINOBUTYRIC ACID. (From Martindale The Extra Pharmacopoeia, 31st ed)
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A family of ribosomal protein S6 kinases that are considered the major physiological kinases for RIBOSOMAL PROTEIN S6. Unlike RIBOSOMAL PROTEIN S6 KINASES, 90KDa the proteins in this family are sensitive to the inhibitory effects of RAPAMYCIN and contain a single kinase domain. They are referred to as 70kDa proteins, however ALTERNATIVE SPLICING of mRNAs for proteins in this class also results in 85kDa variants being formed.
Characteristic cells of granulomatous hypersensitivity. They appear as large, flattened cells with increased endoplasmic reticulum. They are believed to be activated macrophages that have differentiated as a result of prolonged antigenic stimulation. Further differentiation or fusion of epithelioid cells is thought to produce multinucleated giant cells (GIANT CELLS).
A specific pair of GROUP C CHROMSOMES of the human chromosome classification.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
The part of the face above the eyes.
'Gingival neoplasms' are abnormal, uncontrolled growths of tissue originating from the gingiva, which can be benign (non-cancerous) or malignant (cancerous), often manifesting as swellings, ulcerations, or masses within the oral cavity.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Rats bearing mutant genes which are phenotypically expressed in the animals.
Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells.
Cellular antigens that are specific for MELANOMA cells.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
A family of mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. These cells do not have a normal anatomic homolog. (From Fletcher CDM, et. al., World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone, 2002).
An acquired or hereditary condition due to deficiency in the formation of tooth enamel (AMELOGENESIS). It is usually characterized by defective, thin, or malformed DENTAL ENAMEL. Risk factors for enamel hypoplasia include gene mutations, nutritional deficiencies, diseases, and environmental factors.
Diseases of the skin with a genetic component, usually the result of various inborn errors of metabolism.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.
Softening or loss of brain tissue following CEREBRAL INFARCTION; cerebral ischemia (see BRAIN ISCHEMIA), infection, CRANIOCEREBRAL TRAUMA, or other injury. The term is often used during gross pathologic inspection to describe blurred cortical margins and decreased consistency of brain tissue following infarction. Multicystic encephalomalacia refers to the formation of multiple cystic cavities of various sizes in the cerebral cortex of neonates and infants following injury, most notably perinatal hypoxia-ischemic events. (From Davis et al., Textbook of Neuropathology, 2nd ed, p665; J Neuropathol Exp Neurol, 1995 Mar;54(2):268-75)
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
The presence of chyle in the thoracic cavity. (Dorland, 27th ed)

gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. (1/510)

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder leading to the widespread development of benign tumors that often contain giant cells. We show that the Drosophila gene gigas encodes a homolog of TSC2, a gene mutated in half of TSC patients. Clones of gigas mutant cells induced in imaginal discs differentiate normally to produce adult structures. However, the cells in these clones are enlarged and repeat S phase without entering M phase. Our results suggest that the TSC disorder may result from an underlying defect in cell cycle control. We have also identified a Drosophila homolog of TSC1.  (+info)

Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. (2/510)

OBJECTIVES: Intraventricular astrocytomas (subependymal giant cell astrocytomas) of tuberous sclerosis have a poor prognosis due to the obstruction of CSF flow. The aim of this study was to determine whether they could be differentiated during childhood and at an early preclinical stage, from subependymal nodules without any growing potential. METHODS: The first two MRIs of all children referred to this neuropaediatric centre between 1987 and 1996 were retrospectively blindly reviewed. RESULTS: Out of 60 patients, 24 disclosed subependymal nodules localised near the foramen of Monro, and eight of the 24 developed astrocytomas. Subependymal nodules were first detectable on MRI from 1 year of age in all cases and the first MRI evidence of growth occurred between 1 and 9 years (mean 4 years). At an early stage, subependymal nodules had different characteristics in patients who developed subependymal giant cell astrocytomas from those who did not. The nodules over 5 mm in diameter that were incompletely calcified and enhanced by gadolinium were at higher risk of growing, particularly in children with a familial history of tuberous sclerosis. To detect the subependymal giant cell astrocytomas earlier in tuberous sclerosis, it is advisible to systematically perform an MRI examination before 2 years of age and to repeat it every year if the patient has risk factors for developing astrocytomas.  (+info)

Germ-line mosaicism in tuberous sclerosis: how common? (3/510)

Two-thirds of cases of tuberous sclerosis complex (TSC) are sporadic and usually are attributed to new mutations, but unaffected parents sometimes have more than one affected child. We sought to determine how many of these cases represent germ-line mosaicism, as has been reported for other genetic diseases. In our sample of 120 families with TSC, 7 families had two affected children and clinically unaffected parents. These families were tested for mutations in the TSC1 and TSC2 genes, by Southern blotting and by single-strand conformational analysis. Unique variants were detected in six families. Each variant was present and identical in both affected children of a family but was absent in both parents and the unaffected siblings. Sequencing of the variants yielded two frameshift mutations, one missense mutation, and two nonsense mutations in TSC2 and one nonsense mutation in TSC1. To determine which parent contributed the affected gametes, the families were analyzed for linkage to TSC1 and TSC2, by construction of haplotypes with markers flanking the two genes. Linkage analysis and loss-of-heterozygosity studies indicated maternal origin in three families, paternal origin in one family, and either being possible in two families. To evaluate the possibility of low-level somatic mosaicism for TSC, DNA from lymphocytes of members of the six families were tested by allele-specific PCR. In all the families, the mutant allele was detected only in the known affected individuals. We conclude that germ-line mosaicism was present in five families with mutations in the TSC2 gene and in one family with the causative mutation in the TSC1 gene. The results have implications for genetic counseling of families with seemingly sporadic TSC.  (+info)

Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. (4/510)

Tuberous sclerosis (TSC [MIM 191090 and MIM 191100]) is an autosomal dominant disorder characterized by hamartomas in many organs. Two thirds of cases are sporadic and are thought to represent new mutations. TSC is caused by mutations affecting either of the presumed tumor-suppressor genes, TSC1 and TSC2. Both appear to function as tumor suppressors, because somatic loss or intragenic mutation of the corresponding wild-type allele is seen in the associated hamartomas. Here we report the first comprehensive mutation analysis of TSC1 and TSC2 in a cohort of 150 unrelated TSC patients and their families, using heteroduplex and SSCP analysis of all coding exons and using pulsed-field gel electrophoresis and conventional Southern blot analysis and long PCR to screen for large rearrangements. Mutations were characterized in 120 (80%) of the 150 cases, affecting TSC1 in 22 cases and TSC2 in 98 cases. TSC1 mutations were significantly underrepresented in sporadic cases (P=. 000185). Twenty-two patients had TSC2 missense mutations that were found predominantly in the GAP-related domain (eight cases) and in a small region encoded in exons 16 and 17, between nucleotides 1849 and 1859 (eight cases), consistent with the presence of residues performing key functions at these sites. In contrast, all TSC1 mutations were predicted to be truncating, consistent with a structural or adapter role for the encoded protein. Intellectual disability was significantly more frequent in TSC2 sporadic cases than in TSC1 sporadic cases (P=.0145). These data provide the first representative picture of the distribution and spectrum of mutations across the TSC1 and TSC2 loci in clinically ascertained TSC and support a difference in severity of TSC1- and TSC2-associated disease.  (+info)

Dystrophic calcification of the fetal myocardium. (5/510)

Intramural cardiac masses were detected antenatally in three fetuses by echocardiography. The masses were initially thought to be rhabdomyomas. All three pregnancies were terminated and histology showed dystrophic calcification in all, with no evidence of tumour. Therefore, dystrophic calcification of the fetal myocardium may have a similar appearance to single or multiple rhabdomyomas. This should be considered when counselling parents after detection of masses in the fetal heart, particularly when considering the risk of associated tuberous sclerosis.  (+info)

Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation. (6/510)

Tuberous sclerosis complex is an inherited tumour suppressor syndrome, caused by a mutation in either the TSC1 or TSC2 gene. The disease is characterised by a broad phenotypic spectrum that can include seizures, mental retardation, renal dysfunction, and dermatological abnormalities. The TSC1 gene was recently identified and has 23 exons, spanning 45 kb of genomic DNA, and encoding an 8.6 kb mRNA. After screening all 21 coding exons in our collection of 225 unrelated patients, only 29 small mutations were detected, suggesting that TSC1 mutations are under-represented among TSC patients. Almost all TSC1 mutations were small changes leading to a truncated protein, except for a splice site mutation and two in frame deletions in exon 7 and exon 15. No clear difference was observed in the clinical phenotype of patients with an in frame deletion or a frameshift or nonsense mutation. We found the disease causing mutation in 13% of our unrelated set of TSC patients, with more than half of the mutations clustered in exons 15 and 17, and no obvious under-representation of mutations among sporadic cases. In conclusion, we find no support for a genotype-phenotype correlation for the group of TSC1 patients compared to the overall population of TSC patients.  (+info)

End-stage renal failure in adults with the tuberous sclerosis complex. (7/510)

BACKGROUND: Tuberous sclerosis (TSC) is a multisystem disorder encompassing a wide spectrum of pathological renal lesions. Renal involvement is commonly asymptomatic but can result in significant morbidity, and renal failure has been reported. The risk of renal failure in patients with TSC in the UK has not been defined. METHODS: A survey of the 170 members of the European Dialysis and Transplant Association was carried out to identify and collect clinical information on patients with TSC in their renal replacement programme. RESULTS: Ten patients were identified as having end-stage renal failure (ESRF) and TSC, giving an incidence of 1% in patients with TSC and normal intellect. There was a wide spectrum of underlying pathology and clinical presentation within this group. CONCLUSION: ESRF is rare in TSC but does contribute to significant morbidity and mortality in this group.  (+info)

High rate of mosaicism in tuberous sclerosis complex. (8/510)

Six families with mosaicism are identified in a series of 62 unrelated families with a mutation in one of the two tuberous sclerosis complex (TSC) genes, TSC1 or TSC2. In five families, somatic mosaicism was present in a mildly affected parent of an index patient. In one family with clinically unaffected parents, gonadal mosaicism was detected after TSC was found in three children. The detection of mosaicism has consequences for genetic counseling of the families involved, as changed risks apply to individuals with mosaicism, both siblings and parents. Clinical investigation of parents of patients with seemingly sporadic mutations is essential to determine their residual chance of gonadal and/or somatic mosaicism, unless a mosaic pattern is detected in the index patient, proving a de novo event. In our data set, the exclusion of signs of TSC in the parents of a patient with TSC reduced the chance of one of the parents to be a (mosaic) mutation carrier from 10% to 2%. In the five families with somatic mosaicism, the parent was given the diagnosis after the diagnosis was made in the child.  (+info)

Tuberous Sclerosis Complex (TSC) is a rare genetic disorder that causes non-cancerous (benign) tumors to grow in many parts of the body. These tumors can affect the brain, skin, heart, kidneys, eyes, and lungs. The signs and symptoms of TSC can vary widely, depending on where the tumors develop and how severely a person is affected.

The condition is caused by mutations in either the TSC1 or TSC2 gene, which regulate a protein that helps control cell growth and division. When these genes are mutated, the protein is not produced correctly, leading to excessive cell growth and the development of tumors.

TSC is typically diagnosed based on clinical symptoms, medical imaging, and genetic testing. Treatment for TSC often involves a multidisciplinary approach, with specialists in neurology, dermatology, cardiology, nephrology, pulmonology, and ophthalmology working together to manage the various symptoms of the condition. Medications, surgery, and other therapies may be used to help control seizures, developmental delays, skin abnormalities, and other complications of TSC.

Angiomyolipoma is a type of benign tumor that occurs most commonly in the kidney. It is composed of blood vessels (angio-), smooth muscle cells (myo-), and fat cells (lipo-). Angiomyolipomas are usually associated with the genetic disorder tuberous sclerosis complex, but they can also occur spontaneously or as a result of other genetic conditions.

These tumors can vary in size and may cause symptoms such as pain, blood in the urine, or a palpable mass in the abdomen if they grow large enough. In some cases, angiomyolipomas may also be at risk for rupture and bleeding, particularly if they are larger than 4 cm in size.

Treatment options for angiomyolipomas include surveillance with imaging tests, medication to reduce the risk of bleeding, or surgical removal of the tumor. The choice of treatment depends on factors such as the size and location of the tumor, the presence of symptoms, and the patient's overall health.

Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), which includes the brain, spinal cord, and optic nerves. In MS, the immune system mistakenly attacks the protective covering of nerve fibers, called myelin, leading to damage and scarring (sclerosis). This results in disrupted communication between the brain and the rest of the body, causing a variety of neurological symptoms that can vary widely from person to person.

The term "multiple" refers to the numerous areas of scarring that occur throughout the CNS in this condition. The progression, severity, and specific symptoms of MS are unpredictable and may include vision problems, muscle weakness, numbness or tingling, difficulty with balance and coordination, cognitive impairment, and mood changes. There is currently no cure for MS, but various treatments can help manage symptoms, modify the course of the disease, and improve quality of life for those affected.

Rhabdomyoma is a rare, benign tumor that arises from the striated muscle tissue, which is the type of muscle that enables movement and action in the body. These tumors most commonly occur in the heart (cardiac rhabdomyomas) or in the head and neck region (extracardiac rhabdomyomas). Cardiac rhabdomyomas are often associated with genetic disorders such as tuberous sclerosis complex, while extracardiac rhabdomyomas can be found in various locations like the skin, tongue, or skeletal muscles.

Cardiac rhabdomyomas typically appear in infancy or early childhood and may not cause any symptoms. However, they can potentially lead to complications such as heart rhythm abnormalities, obstruction of blood flow, or heart failure. Extracardiac rhabdomyomas are usually slow-growing and asymptomatic but can cause issues depending on their size and location. Surgical removal may be necessary if the tumor interferes with vital functions or causes discomfort.

It is essential to note that while rhabdomyomas are generally benign, they can undergo malignant transformation in rare cases, leading to a more aggressive form called rhabdomyosarcoma. Regular follow-ups and monitoring are crucial for early detection and management of any changes in the tumor's behavior.

Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that primarily affects women of childbearing age. It is characterized by the abnormal growth of smooth muscle cells in the airways, blood vessels, and lymphatic system of the lungs. These cells can form cysts and lesions that can obstruct the airways and cause lung function to decline over time.

LAM can also affect other organs, such as the kidneys, where it can cause angiomyolipomas (benign tumors composed of blood vessels, muscle cells, and fat). In some cases, LAM may be associated with tuberous sclerosis complex (TSC), a genetic disorder that causes benign tumors to grow in various organs of the body.

The exact cause of LAM is not fully understood, but it is believed to be related to mutations in the TSC1 or TSC2 genes, which regulate cell growth and division. There is currently no cure for LAM, but treatments such as lung transplantation and medications that suppress the growth of smooth muscle cells may help manage symptoms and slow disease progression.

Tumor suppressor proteins are a type of regulatory protein that helps control the cell cycle and prevent cells from dividing and growing in an uncontrolled manner. They work to inhibit tumor growth by preventing the formation of tumors or slowing down their progression. These proteins can repair damaged DNA, regulate gene expression, and initiate programmed cell death (apoptosis) if the damage is too severe for repair.

Mutations in tumor suppressor genes, which provide the code for these proteins, can lead to a decrease or loss of function in the resulting protein. This can result in uncontrolled cell growth and division, leading to the formation of tumors and cancer. Examples of tumor suppressor proteins include p53, Rb (retinoblastoma), and BRCA1/2.

Sclerosis is a medical term that refers to the abnormal hardening or scarring of body tissues, particularly in the context of various degenerative diseases affecting the nervous system. The term "sclerosis" comes from the Greek word "skleros," which means hard. In these conditions, the normally flexible and adaptable nerve cells or their protective coverings (myelin sheath) become rigid and inflexible due to the buildup of scar tissue or abnormal protein deposits.

There are several types of sclerosis, but one of the most well-known is multiple sclerosis (MS). In MS, the immune system mistakenly attacks the myelin sheath surrounding nerve fibers in the brain and spinal cord, leading to scarring and damage that disrupts communication between the brain and the rest of the body. This results in a wide range of symptoms, such as muscle weakness, numbness, vision problems, balance issues, and cognitive impairment.

Other conditions that involve sclerosis include:

1. Amyotrophic lateral sclerosis (ALS): Also known as Lou Gehrig's disease, ALS is a progressive neurodegenerative disorder affecting motor neurons in the brain and spinal cord, leading to muscle weakness, stiffness, and atrophy.
2. Systemic sclerosis: A rare autoimmune connective tissue disorder characterized by thickening and hardening of the skin and internal organs due to excessive collagen deposition.
3. Plaque psoriasis: A chronic inflammatory skin condition marked by red, scaly patches (plaques) resulting from rapid turnover and accumulation of skin cells.
4. Adhesive capsulitis: Also known as frozen shoulder, this condition involves stiffening and thickening of the shoulder joint's capsule due to scarring or inflammation, leading to limited mobility and pain.

TOR (Target Of Rapamycin) Serine-Threonine Kinases are a family of conserved protein kinases that play crucial roles in the regulation of cell growth, proliferation, and metabolism in response to various environmental cues such as nutrients, growth factors, and energy status. They are named after their ability to phosphorylate serine and threonine residues on target proteins.

Mammalian cells express two distinct TOR kinases, mTORC1 and mTORC2, which have different protein compositions and functions. mTORC1 is rapamycin-sensitive and regulates cell growth, proliferation, and metabolism by phosphorylating downstream targets such as p70S6 kinase and 4E-BP1, thereby controlling protein synthesis, autophagy, and lysosome biogenesis. mTORC2 is rapamycin-insensitive and regulates cell survival, cytoskeleton organization, and metabolism by phosphorylating AGC kinases such as AKT and PKCα.

Dysregulation of TOR Serine-Threonine Kinases has been implicated in various human diseases, including cancer, diabetes, and neurological disorders. Therefore, targeting TOR kinases has emerged as a promising therapeutic strategy for the treatment of these diseases.

Facial neoplasms refer to abnormal growths or tumors that develop in the tissues of the face. These growths can be benign (non-cancerous) or malignant (cancerous). Facial neoplasms can occur in any of the facial structures, including the skin, muscles, bones, nerves, and glands.

Benign facial neoplasms are typically slow-growing and do not spread to other parts of the body. Examples include papillomas, hemangiomas, and neurofibromas. While these tumors are usually harmless, they can cause cosmetic concerns or interfere with normal facial function.

Malignant facial neoplasms, on the other hand, can be aggressive and invasive. They can spread to other parts of the face, as well as to distant sites in the body. Common types of malignant facial neoplasms include basal cell carcinoma, squamous cell carcinoma, and melanoma.

Treatment for facial neoplasms depends on several factors, including the type, size, location, and stage of the tumor. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. It is important to seek medical attention promptly if you notice any unusual growths or changes in the skin or tissues of your face.

Angiofibroma is a benign tumor that most commonly occurs in the nasopharynx (the upper part of the throat behind the nose) in adolescents and young adults, particularly males. It is composed of blood vessels and fibrous tissue. Angiofibromas are also known as juvenile nasopharyngeal angiofibromas because they often occur in young people and originate in the nasopharynx.

These tumors can cause symptoms such as nosebleeds, nasal congestion, and difficulty breathing through the nose. In some cases, they may also cause hearing problems or double vision. Angiofibromas are typically treated with surgery to remove the tumor. Radiation therapy may also be used in some cases.

It is important to note that angiofibroma is a specific type of tumor that has distinct characteristics and is treated differently from other types of tumors. If you have any concerns about this condition or if you are experiencing symptoms that you think may be related to an angiofibroma, it is important to consult with a healthcare professional for proper diagnosis and treatment.

A hamartoma is a benign tumor-like growth that is composed of an unusual mixture of cells and tissues that are normally found in the affected area. These growths can occur anywhere in the body, but they are most commonly found in the skin, lungs, and brain. Hamartomas are typically slow growing and do not spread to other parts of the body (metastasize). They are usually harmless, but in some cases, they may cause symptoms or complications depending on their size and location. In general, hamartomas do not require treatment unless they are causing problems.

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord responsible for controlling voluntary muscle movements, such as speaking, walking, breathing, and swallowing. The condition is characterized by the degeneration of motor neurons in the brain (upper motor neurons) and spinal cord (lower motor neurons), leading to their death.

The term "amyotrophic" comes from the Greek words "a" meaning no or negative, "myo" referring to muscle, and "trophic" relating to nutrition. When a motor neuron degenerates and can no longer send impulses to the muscle, the muscle becomes weak and eventually atrophies due to lack of use.

The term "lateral sclerosis" refers to the hardening or scarring (sclerosis) of the lateral columns of the spinal cord, which are primarily composed of nerve fibers that carry information from the brain to the muscles.

ALS is often called Lou Gehrig's disease, named after the famous American baseball player who was diagnosed with the condition in 1939. The exact cause of ALS remains unknown, but it is believed to involve a combination of genetic and environmental factors. There is currently no cure for ALS, and treatment primarily focuses on managing symptoms and maintaining quality of life.

The progression of ALS varies from person to person, with some individuals experiencing rapid decline over just a few years, while others may have a more slow-progressing form of the disease that lasts several decades. The majority of people with ALS die from respiratory failure within 3 to 5 years after the onset of symptoms. However, approximately 10% of those affected live for 10 or more years following diagnosis.

Sirolimus is a medication that belongs to a class of drugs called immunosuppressants. It is also known as rapamycin. Sirolimus works by inhibiting the mammalian target of rapamycin (mTOR), which is a protein that plays a key role in cell growth and division.

Sirolimus is primarily used to prevent rejection of transplanted organs, such as kidneys, livers, and hearts. It works by suppressing the activity of the immune system, which can help to reduce the risk of the body rejecting the transplanted organ. Sirolimus is often used in combination with other immunosuppressive drugs, such as corticosteroids and calcineurin inhibitors.

Sirolimus is also being studied for its potential therapeutic benefits in a variety of other conditions, including cancer, tuberous sclerosis complex, and lymphangioleiomyomatosis. However, more research is needed to fully understand the safety and efficacy of sirolimus in these contexts.

It's important to note that sirolimus can have significant side effects, including increased risk of infections, mouth sores, high blood pressure, and kidney damage. Therefore, it should only be used under the close supervision of a healthcare provider.

Malformations of Cortical Development (MCDs) are a group of congenital brain abnormalities that occur during the development and organization of the cerebral cortex, which is the brain region responsible for higher cognitive functions. These malformations result from disruptions in neuronal migration, proliferation, or organization, leading to varying degrees of cortical thickness, folding, and structural integrity.

MCDs can be classified into several subtypes based on their distinct neuroimaging and histopathological features. Some common MCD subtypes include:

1. Lissencephaly (smooth brain): A severe malformation characterized by the absence of normal gyral and sulcal patterns, resulting in a smooth cortical surface. This is caused by defects in neuronal migration during early development.
2. Polymicrogyria (many small folds): A condition where the cortex has an excessive number of small, irregular gyri, leading to thickened and disorganized cortical layers. This can be focal or diffuse and is caused by abnormal neuronal migration or organization during mid to late development.
3. Schizencephaly (cleft brain): A malformation characterized by a linear cleft or gap in the cerebral cortex, extending from the pial surface to the ventricular system. This can be unilateral or bilateral and is caused by disruptions in neuronal migration and/or cortical organization during early development.
4. Heterotopias (misplaced cells): A condition where groups of neurons are abnormally located within the white matter or at the gray-white matter junction, instead of their normal position in the cerebral cortex. This can be focal or diffuse and is caused by defects in neuronal migration during early development.
5. Focal cortical dysplasia (abnormal localized tissue): A condition characterized by abnormal cortical architecture, including disorganized lamination, enlarged neurons, and heterotopic neurons. This can be focal or multifocal and is caused by defects in cortical organization during late development.

MCDs are often associated with neurological symptoms such as epilepsy, intellectual disability, motor deficits, and behavioral abnormalities. The severity of these symptoms depends on the type, location, and extent of the malformation.

Heart neoplasms are abnormal growths or tumors that develop within the heart tissue. They can be benign (noncancerous) or malignant (cancerous). Benign tumors, such as myxomas and rhabdomyomas, are typically slower growing and less likely to spread, but they can still cause serious complications if they obstruct blood flow or damage heart valves. Malignant tumors, such as angiosarcomas and rhabdomyosarcomas, are fast-growing and have a higher risk of spreading to other parts of the body. Symptoms of heart neoplasms can include shortness of breath, chest pain, fatigue, and irregular heart rhythms. Treatment options depend on the type, size, and location of the tumor, and may include surgery, radiation therapy, or chemotherapy.

Medical Definition of "Multiprotein Complexes" :

Multiprotein complexes are large molecular assemblies composed of two or more proteins that interact with each other to carry out specific cellular functions. These complexes can range from relatively simple dimers or trimers to massive structures containing hundreds of individual protein subunits. They are formed through a process known as protein-protein interaction, which is mediated by specialized regions on the protein surface called domains or motifs.

Multiprotein complexes play critical roles in many cellular processes, including signal transduction, gene regulation, DNA replication and repair, protein folding and degradation, and intracellular transport. The formation of these complexes is often dynamic and regulated in response to various stimuli, allowing for precise control of their function.

Disruption of multiprotein complexes can lead to a variety of diseases, including cancer, neurodegenerative disorders, and infectious diseases. Therefore, understanding the structure, composition, and regulation of these complexes is an important area of research in molecular biology and medicine.

Systemic Scleroderma, also known as Systemic Sclerosis (SSc), is a rare, chronic autoimmune disease that involves the abnormal growth and accumulation of collagen in various connective tissues, blood vessels, and organs throughout the body. This excessive collagen production leads to fibrosis or scarring, which can cause thickening, hardening, and tightening of the skin and damage to internal organs such as the heart, lungs, kidneys, and gastrointestinal tract.

Systemic Scleroderma is characterized by two main features: small blood vessel abnormalities (Raynaud's phenomenon) and fibrosis. The disease can be further classified into two subsets based on the extent of skin involvement: limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc).

Limited cutaneous systemic sclerosis affects the skin distally, typically involving fingers, hands, forearms, feet, lower legs, and face. It is often associated with Raynaud's phenomenon, calcinosis, telangiectasias, and pulmonary arterial hypertension.

Diffuse cutaneous systemic sclerosis involves more extensive skin thickening and fibrosis that spreads proximally to affect the trunk, upper arms, thighs, and face. It is commonly associated with internal organ involvement, such as interstitial lung disease, heart disease, and kidney problems.

The exact cause of Systemic Scleroderma remains unknown; however, it is believed that genetic, environmental, and immunological factors contribute to its development. There is currently no cure for Systemic Scleroderma, but various treatments can help manage symptoms, slow disease progression, and improve quality of life.

Sebaceous gland neoplasms are abnormal growths or tumors that develop in the sebaceous glands, which are small oil-producing glands found in the skin. These glands are responsible for producing sebum, a natural oil that helps keep the skin and hair moisturized. Sebaceous gland neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign sebaceous gland neoplasms include:

* Seborrheic keratosis: These are common, harmless growths that appear as rough, scaly patches on the skin. They can be tan, brown, or black in color and vary in size from small to large.
* Sebaceous adenoma: This is a benign tumor that arises from the sebaceous glands. It typically appears as a small, yellowish bump on the skin.

Malignant sebaceous gland neoplasms include:

* Sebaceous carcinoma: This is a rare but aggressive form of skin cancer that arises from the sebaceous glands. It often appears as a hard, painless nodule on the eyelid or other areas of the face and can spread to other parts of the body if left untreated.
* Basal cell carcinoma: While not exclusively a sebaceous gland neoplasm, basal cell carcinomas can sometimes arise from the sebaceous glands. These are slow-growing but invasive skin cancers that typically appear as pearly or flesh-colored bumps on the skin.

It is important to have any new or changing growths on the skin evaluated by a healthcare professional to determine whether they are benign or malignant and to develop an appropriate treatment plan if necessary.

Infantile spasms, also known as West syndrome, is a rare but serious type of epilepsy that affects infants typically between 4-8 months of age. The spasms are characterized by sudden, brief, and frequent muscle jerks or contractions, often involving the neck, trunk, and arms. These spasms usually occur in clusters and may cause the infant to bend forward or stretch out. Infantile spasms can be a symptom of various underlying neurological conditions and are often associated with developmental delays and regression. Early recognition and treatment are crucial for improving outcomes.

Monomeric GTP-binding proteins, also known as small GTPases, are a family of proteins that bind and hydrolyze guanosine triphosphate (GTP) to guanosine diphosphate (GDP). These proteins function as molecular switches, cycling between an inactive GDP-bound state and an active GTP-bound state. They play crucial roles in regulating various cellular processes such as signal transduction, vesicle trafficking, cytoskeleton organization, and cell cycle progression. Examples of monomeric GTP-binding proteins include Ras, Rho, Rab, and Ran families.

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures. These seizures are caused by abnormal electrical activity in the brain, which can result in a wide range of symptoms, including convulsions, loss of consciousness, and altered sensations or behaviors. Epilepsy can have many different causes, including genetic factors, brain injury, infection, or stroke. In some cases, the cause may be unknown.

There are many different types of seizures that can occur in people with epilepsy, and the specific type of seizure will depend on the location and extent of the abnormal electrical activity in the brain. Some people may experience only one type of seizure, while others may have several different types. Seizures can vary in frequency, from a few per year to dozens or even hundreds per day.

Epilepsy is typically diagnosed based on the patient's history of recurrent seizures and the results of an electroencephalogram (EEG), which measures the electrical activity in the brain. Imaging tests such as MRI or CT scans may also be used to help identify any structural abnormalities in the brain that may be contributing to the seizures.

While there is no cure for epilepsy, it can often be effectively managed with medication. In some cases, surgery may be recommended to remove the area of the brain responsible for the seizures. With proper treatment and management, many people with epilepsy are able to lead normal, productive lives.

Kidney neoplasms refer to abnormal growths or tumors in the kidney tissues that can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various types of kidney cells, including the renal tubules, glomeruli, and the renal pelvis.

Malignant kidney neoplasms are also known as kidney cancers, with renal cell carcinoma being the most common type. Benign kidney neoplasms include renal adenomas, oncocytomas, and angiomyolipomas. While benign neoplasms are generally not life-threatening, they can still cause problems if they grow large enough to compromise kidney function or if they undergo malignant transformation.

Early detection and appropriate management of kidney neoplasms are crucial for improving patient outcomes and overall prognosis. Regular medical check-ups, imaging studies, and urinalysis can help in the early identification of these growths, allowing for timely intervention and treatment.

Repressor proteins are a type of regulatory protein in molecular biology that suppress the transcription of specific genes into messenger RNA (mRNA) by binding to DNA. They function as part of gene regulation processes, often working in conjunction with an operator region and a promoter region within the DNA molecule. Repressor proteins can be activated or deactivated by various signals, allowing for precise control over gene expression in response to changing cellular conditions.

There are two main types of repressor proteins:

1. DNA-binding repressors: These directly bind to specific DNA sequences (operator regions) near the target gene and prevent RNA polymerase from transcribing the gene into mRNA.
2. Allosteric repressors: These bind to effector molecules, which then cause a conformational change in the repressor protein, enabling it to bind to DNA and inhibit transcription.

Repressor proteins play crucial roles in various biological processes, such as development, metabolism, and stress response, by controlling gene expression patterns in cells.

Ribosomal Protein S6 Kinases (RSKs) are a family of serine/threonine protein kinases that play a crucial role in the regulation of cell growth, proliferation, and survival. They are so named because they phosphorylate and regulate the function of the ribosomal protein S6, which is a component of the 40S ribosomal subunit involved in protein synthesis.

RSKs are activated by various signals, including growth factors, hormones, and mitogens, through a cascade of phosphorylation events involving several upstream kinases such as MAPK/ERK kinase (MEK) and extracellular signal-regulated kinase (ERK). Once activated, RSKs phosphorylate a wide range of downstream targets, including transcription factors, regulators of translation, and cytoskeletal proteins, thereby modulating their activities and functions.

There are four isoforms of RSKs in humans, namely RSK1, RSK2, RSK3, and RSK4, which share a common structural organization and functional domains, including an N-terminal kinase domain, a C-terminal kinase domain, and a linker region that contains several regulatory motifs. Dysregulation of RSKs has been implicated in various pathological conditions, including cancer, cardiovascular diseases, neurological disorders, and diabetes, making them attractive targets for therapeutic intervention.

Multiple Sclerosis (MS), Chronic Progressive is a form of Multiple Sclerosis, a chronic autoimmune disease that affects the central nervous system (CNS). In this form, the disease follows a steady progression with no distinct relapses or remissions. The symptoms worsen over time, leading to a decline in physical functioning and increased disability.

The term "chronic progressive" is used to describe the course of the disease, which is characterized by a continuous worsening of neurological functions from the onset, or after an initial relapsing-remitting phase. There are two types of chronic progressive MS: primary and secondary.

1. Primary Chronic Progressive MS (PCP): This form of MS shows a steady progression of symptoms from the beginning, with no distinct remissions or relapses. The disability accumulates gradually over time, and the person may experience varying degrees of physical and cognitive impairment.

2. Secondary Chronic Progressive MS (SCP): In this form, an individual initially has a relapsing-remitting course of MS (RRMS), characterized by unpredictable relapses followed by periods of partial or complete recovery (remissions). However, after some time, the disease transitions to a steady progression of symptoms and disability, even without distinct relapses. This is known as secondary chronic progressive MS.

The exact cause of Multiple Sclerosis remains unknown; however, it is believed to be influenced by genetic, environmental, and immunological factors. The disease involves the immune system attacking the myelin sheath, a protective covering surrounding nerve fibers in the CNS. This results in lesions or scars (scleroses) that disrupt communication between the brain, spinal cord, and other parts of the body, leading to various physical, cognitive, and sensory symptoms.

Management of Chronic Progressive MS typically involves a multidisciplinary approach, focusing on symptom management, rehabilitation, and maintaining quality of life. Currently, there are no approved disease-modifying therapies specifically for chronic progressive MS; however, some medications used to treat relapsing-remitting MS may help slow the progression of disability in certain individuals with secondary chronic progressive MS.

A fibroma is a benign (non-cancerous) tumor that consists primarily of fibrous or connective tissue. It can occur in various parts of the body, including the skin, mouth, and internal organs. The term "fibroma" is often used to describe any benign fibrous growth, but there are specific types of fibromas such as dermatofibroma (found in the skin), oral fibroma (found in the mouth), and benign fibrous histiocytoma (found in soft tissues).

It's important to note that while fibromas are generally harmless, they can cause discomfort or problems depending on their size and location. If a fibroma is causing issues or there's concern about its growth or malignancy, it should be evaluated by a healthcare professional for potential removal or further assessment.

Pigmentation disorders are conditions that affect the production or distribution of melanin, the pigment responsible for the color of skin, hair, and eyes. These disorders can cause changes in the color of the skin, resulting in areas that are darker (hyperpigmentation) or lighter (hypopigmentation) than normal. Examples of pigmentation disorders include melasma, age spots, albinism, and vitiligo. The causes, symptoms, and treatments for these conditions can vary widely, so it is important to consult a healthcare provider for an accurate diagnosis and treatment plan.

Proteins are complex, large molecules that play critical roles in the body's functions. They are made up of amino acids, which are organic compounds that are the building blocks of proteins. Proteins are required for the structure, function, and regulation of the body's tissues and organs. They are essential for the growth, repair, and maintenance of body tissues, and they play a crucial role in many biological processes, including metabolism, immune response, and cellular signaling. Proteins can be classified into different types based on their structure and function, such as enzymes, hormones, antibodies, and structural proteins. They are found in various foods, especially animal-derived products like meat, dairy, and eggs, as well as plant-based sources like beans, nuts, and grains.

Medical Definition:

Magnetic Resonance Imaging (MRI) is a non-invasive diagnostic imaging technique that uses a strong magnetic field and radio waves to create detailed cross-sectional or three-dimensional images of the internal structures of the body. The patient lies within a large, cylindrical magnet, and the scanner detects changes in the direction of the magnetic field caused by protons in the body. These changes are then converted into detailed images that help medical professionals to diagnose and monitor various medical conditions, such as tumors, injuries, or diseases affecting the brain, spinal cord, heart, blood vessels, joints, and other internal organs. MRI does not use radiation like computed tomography (CT) scans.

Macrocephaly is a medical term that refers to a condition where an individual has an abnormally large head size. It is typically defined as a head circumference (the measurement of the head's perimeter) that is more than two standard deviations above the average for age, gender, and height.

Macrocephaly can be caused by various factors, including genetic disorders, brain abnormalities, developmental delays, and hydrocephalus (the accumulation of cerebrospinal fluid in the brain). In some cases, macrocephaly may not indicate any underlying medical condition, and the person's head size may remain proportionate to their body as they grow.

It is essential to monitor individuals with macrocephaly for any associated neurological or developmental issues and provide appropriate medical interventions if necessary.

Cystadenoma is a type of benign tumor (not cancerous), which arises from glandular epithelial cells and is covered by a thin layer of connective tissue. These tumors can develop in various locations within the body, including the ovaries, pancreas, and other organs that contain glands.

There are two main types of cystadenomas: serous and mucinous. Serous cystadenomas are filled with a clear or watery fluid, while mucinous cystadenomas contain a thick, gelatinous material. Although they are generally not harmful, these tumors can grow quite large and cause discomfort or other symptoms due to their size or location. In some cases, cystadenomas may undergo malignant transformation and develop into cancerous tumors, known as cystadenocarcinomas. Regular medical follow-up and monitoring are essential for individuals diagnosed with cystadenomas to ensure early detection and treatment of any potential complications.

Hypopigmentation is a medical term that refers to a condition where there is a decrease in the amount of pigment (melanin) in the skin, resulting in lighter patches or spots on the skin. This can occur due to various reasons such as skin injuries, certain skin disorders like vitiligo, fungal infections, burns, or as a side effect of some medical treatments like chemotherapy or radiation therapy. It is different from albinism, which is a genetic condition where the body is unable to produce melanin at all.

Protein kinases are a group of enzymes that play a crucial role in many cellular processes by adding phosphate groups to other proteins, a process known as phosphorylation. This modification can activate or deactivate the target protein's function, thereby regulating various signaling pathways within the cell. Protein kinases are essential for numerous biological functions, including metabolism, signal transduction, cell cycle progression, and apoptosis (programmed cell death). Abnormal regulation of protein kinases has been implicated in several diseases, such as cancer, diabetes, and neurological disorders.

The brain is the central organ of the nervous system, responsible for receiving and processing sensory information, regulating vital functions, and controlling behavior, movement, and cognition. It is divided into several distinct regions, each with specific functions:

1. Cerebrum: The largest part of the brain, responsible for higher cognitive functions such as thinking, learning, memory, language, and perception. It is divided into two hemispheres, each controlling the opposite side of the body.
2. Cerebellum: Located at the back of the brain, it is responsible for coordinating muscle movements, maintaining balance, and fine-tuning motor skills.
3. Brainstem: Connects the cerebrum and cerebellum to the spinal cord, controlling vital functions such as breathing, heart rate, and blood pressure. It also serves as a relay center for sensory information and motor commands between the brain and the rest of the body.
4. Diencephalon: A region that includes the thalamus (a major sensory relay station) and hypothalamus (regulates hormones, temperature, hunger, thirst, and sleep).
5. Limbic system: A group of structures involved in emotional processing, memory formation, and motivation, including the hippocampus, amygdala, and cingulate gyrus.

The brain is composed of billions of interconnected neurons that communicate through electrical and chemical signals. It is protected by the skull and surrounded by three layers of membranes called meninges, as well as cerebrospinal fluid that provides cushioning and nutrients.

Intellectual disability (ID) is a term used when there are significant limitations in both intellectual functioning and adaptive behavior, which covers many everyday social and practical skills. This disability originates before the age of 18.

Intellectual functioning, also known as intelligence, refers to general mental capacity, such as learning, reasoning, problem-solving, and other cognitive skills. Adaptive behavior includes skills needed for day-to-day life, such as communication, self-care, social skills, safety judgement, and basic academic skills.

Intellectual disability is characterized by below-average intelligence or mental ability and a lack of skills necessary for day-to-day living. It can be mild, moderate, severe, or profound, depending on the degree of limitation in intellectual functioning and adaptive behavior.

It's important to note that people with intellectual disabilities have unique strengths and limitations, just like everyone else. With appropriate support and education, they can lead fulfilling lives and contribute to their communities in many ways.

A seizure is an uncontrolled, abnormal firing of neurons (brain cells) that can cause various symptoms such as convulsions, loss of consciousness, altered awareness, or changes in behavior. Seizures can be caused by a variety of factors including epilepsy, brain injury, infection, toxic substances, or genetic disorders. They can also occur without any identifiable cause, known as idiopathic seizures. Seizures are a medical emergency and require immediate attention.

Astrocytoma is a type of brain tumor that arises from astrocytes, which are star-shaped glial cells in the brain. These tumors can occur in various parts of the brain and can have different grades of malignancy, ranging from low-grade (I or II) to high-grade (III or IV). Low-grade astrocytomas tend to grow slowly and may not cause any symptoms for a long time, while high-grade astrocytomas are more aggressive and can grow quickly, causing neurological problems.

Symptoms of astrocytoma depend on the location and size of the tumor but may include headaches, seizures, weakness or numbness in the limbs, difficulty speaking or swallowing, changes in vision or behavior, and memory loss. Treatment options for astrocytomas include surgery, radiation therapy, chemotherapy, or a combination of these approaches. The prognosis for astrocytoma varies widely depending on the grade and location of the tumor, as well as the age and overall health of the patient.

Human chromosome pair 16 consists of two rod-shaped structures present in the nucleus of each cell in the human body. Each chromosome is made up of DNA tightly coiled around histone proteins, forming a complex structure called a chromatin.

Chromosomes come in pairs, with one chromosome inherited from each parent. Chromosome pair 16 contains two homologous chromosomes, which are similar in size, shape, and genetic content but may have slight variations due to differences in the DNA sequences inherited from each parent.

Chromosome pair 16 is one of the 22 autosomal pairs, meaning it contains non-sex chromosomes that are present in both males and females. Chromosome 16 is a medium-sized chromosome, and it contains around 2,800 genes that provide instructions for making proteins and regulating various cellular processes.

Abnormalities in chromosome pair 16 can lead to genetic disorders such as chronic myeloid leukemia, some forms of mental retardation, and other developmental abnormalities.

Vigabatrin is an anticonvulsant medication used to treat certain types of seizures in adults and children. It works by reducing the abnormal excitement in the brain. The medical definition of Vigabatrin is: a irreversible inhibitor of GABA transaminase, which results in increased levels of gamma-aminobutyric acid (GABA) in the central nervous system. This medication is used as an adjunctive treatment for complex partial seizures and is available in oral form for administration.

It's important to note that Vigabatrin can cause serious side effects, including permanent vision loss, and its use should be closely monitored by a healthcare professional. It is also classified as a pregnancy category C medication, which means it may harm an unborn baby and should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Signal transduction is the process by which a cell converts an extracellular signal, such as a hormone or neurotransmitter, into an intracellular response. This involves a series of molecular events that transmit the signal from the cell surface to the interior of the cell, ultimately resulting in changes in gene expression, protein activity, or metabolism.

The process typically begins with the binding of the extracellular signal to a receptor located on the cell membrane. This binding event activates the receptor, which then triggers a cascade of intracellular signaling molecules, such as second messengers, protein kinases, and ion channels. These molecules amplify and propagate the signal, ultimately leading to the activation or inhibition of specific cellular responses.

Signal transduction pathways are highly regulated and can be modulated by various factors, including other signaling molecules, post-translational modifications, and feedback mechanisms. Dysregulation of these pathways has been implicated in a variety of diseases, including cancer, diabetes, and neurological disorders.

Ribosomal Protein S6 Kinases, 70-kDa (p70S6K or RPS6KB1) are serine/threonine protein kinases that play a crucial role in the regulation of cell growth and metabolism. They are so named because they phosphorylate the 40S ribosomal protein S6, which is a component of the small ribosomal subunit. This phosphorylation event is believed to contribute to the control of protein synthesis rates in response to various cellular signals, including growth factors and nutrients.

p70S6K is activated by the PI3K/AKT/mTOR signaling pathway, which is a critical regulator of cell growth, proliferation, and survival. The activation of p70S6K involves a series of phosphorylation events, primarily by mTORC1 (mammalian target of rapamycin complex 1). Once activated, p70S6K promotes several processes related to cell growth, such as:

1. Translation initiation and elongation: Phosphorylation of ribosomal protein S6 and other translation factors enhances the translation of specific mRNAs involved in cell cycle progression, ribosome biogenesis, and metabolic enzymes.
2. Nucleolar formation and rRNA transcription: p70S6K promotes nucleolar formation and increases rRNA transcription by phosphorylating upstream binding factor (UBF), a critical transcriptional regulator of rDNA.
3. mRNA stability: Phosphorylation of certain RNA-binding proteins, such as 4E-BP1, by p70S6K can lead to increased mRNA stability and translation efficiency.

Abnormal regulation of p70S6K has been implicated in various diseases, including cancer, diabetes, and cardiovascular disorders. Therefore, understanding the function and regulation of p70S6K is essential for developing novel therapeutic strategies targeting these conditions.

Epithelioid cells are a type of cell that can be found in certain types of tissue in the body, including connective tissue and some organs. These cells have a characteristic appearance under a microscope, with an enlarged, oval or round shape and a pale, abundant cytoplasm. They may also have a nucleus that is centrally located and has a uniform, rounded shape.

Epithelioid cells are often seen in the context of inflammation or disease, particularly in relation to granulomatous disorders such as sarcoidosis and tuberculosis. In these conditions, epithelioid cells can form clusters known as granulomas, which are a hallmark of the diseases. The exact function of epithelioid cells is not fully understood, but they are thought to play a role in the immune response and may help to contain and eliminate foreign substances or pathogens from the body.

Human chromosome pair 9 consists of two rod-shaped structures present in the nucleus of each cell of the human body. Each member of the pair contains thousands of genes and other genetic material, encoded in the form of DNA molecules. The two chromosomes in a pair are identical or very similar to each other in terms of their size, shape, and genetic makeup.

Chromosome 9 is one of the autosomal chromosomes, meaning that it is not a sex chromosome (X or Y) and is present in two copies in all cells of the body, regardless of sex. Chromosome 9 is a medium-sized chromosome, and it is estimated to contain around 135 million base pairs of DNA and approximately 1200 genes.

Chromosome 9 contains several important genes that are associated with various human traits and diseases. For example, mutations in the gene that encodes the protein APOE on chromosome 9 have been linked to an increased risk of developing Alzheimer's disease. Additionally, variations in the gene that encodes the protein EGFR on chromosome 9 have been associated with an increased risk of developing certain types of cancer.

Overall, human chromosome pair 9 plays a critical role in the development and function of the human body, and variations in its genetic makeup can contribute to a wide range of traits and diseases.

Tumor suppressor genes are a type of gene that helps to regulate and prevent cells from growing and dividing too rapidly or in an uncontrolled manner. They play a critical role in preventing the formation of tumors and cancer. When functioning properly, tumor suppressor genes help to repair damaged DNA, control the cell cycle, and trigger programmed cell death (apoptosis) when necessary. However, when these genes are mutated or altered, they can lose their ability to function correctly, leading to uncontrolled cell growth and the development of tumors. Examples of tumor suppressor genes include TP53, BRCA1, and BRCA2.

A forehead, in medical terms, refers to the portion of the human skull that lies immediately above the eyes and serves as an attachment site for the frontal bone. It is a common area for the examination of various clinical signs, such as assessing the level of consciousness (by checking if the patient's eyebrows or eyelids twitch in response to a light touch) or looking for signs of increased intracranial pressure (such as bulging fontanelles in infants). Additionally, the forehead is often used as a site for non-invasive procedures like Botox injections.

Gingival neoplasms refer to abnormal growths or tumors that occur in the gingiva, which are the part of the gums that surround the teeth. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms include conditions such as fibromas, papillomas, and hemangiomas, while malignant neoplasms are typically squamous cell carcinomas.

Gingival neoplasms can present with a variety of symptoms, including swelling, bleeding, pain, and loose teeth. They may also cause difficulty with chewing, speaking, or swallowing. The exact cause of these neoplasms is not always known, but risk factors include tobacco use, alcohol consumption, poor oral hygiene, and certain viral infections.

Diagnosis of gingival neoplasms typically involves a thorough clinical examination, including a dental exam and biopsy. Treatment options depend on the type and stage of the neoplasm, but may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Regular dental check-ups and good oral hygiene practices can help to detect gingival neoplasms at an early stage and improve treatment outcomes.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

I'm sorry for any confusion, but "Rats, Mutant Strains" is not a recognized medical term or concept. It may be a term used in science fiction, gaming, or other non-medical contexts to refer to genetically modified rats with altered characteristics. However, in the field of medical research, scientists do conduct studies using various strains of lab rats, some of which have been selectively bred or genetically modified to exhibit specific traits, but these are not referred to as "mutant strains." If you have any questions related to medical definitions or concepts, I'd be happy to help with those!

Neuropeptides are small protein-like molecules that are used by neurons to communicate with each other and with other cells in the body. They are produced in the cell body of a neuron, processed from larger precursor proteins, and then transported to the nerve terminal where they are stored in secretory vesicles. When the neuron is stimulated, the vesicles fuse with the cell membrane and release their contents into the extracellular space.

Neuropeptides can act as neurotransmitters or neuromodulators, depending on their target receptors and the duration of their effects. They play important roles in a variety of physiological processes, including pain perception, appetite regulation, stress response, and social behavior. Some neuropeptides also have hormonal functions, such as oxytocin and vasopressin, which are produced in the hypothalamus and released into the bloodstream to regulate reproductive and cardiovascular function, respectively.

There are hundreds of different neuropeptides that have been identified in the nervous system, and many of them have multiple functions and interact with other signaling molecules to modulate neural activity. Dysregulation of neuropeptide systems has been implicated in various neurological and psychiatric disorders, such as chronic pain, addiction, depression, and anxiety.

Melanoma-specific antigens are proteins or other molecules that are present on melanoma cells but not normally found on healthy cells in the body. These antigens can be recognized by the immune system as foreign and trigger an immune response, making them potential targets for immunotherapy treatments for melanoma.

There are two main types of melanoma-specific antigens: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not found on normal cells, while TAAs are overexpressed or mutated versions of proteins that are also present in normal cells.

Examples of melanoma-specific antigens include Melan-A/MART-1, gp100, and tyrosinase. These antigens have been studied extensively as targets for cancer vaccines, adoptive cell therapy, and other immunotherapy approaches to treat melanoma.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

Perivascular Epithelioid Cell Neoplasms (PEComas) are a rare group of mesenchymal tumors that demonstrate unique clinical and pathological features. These neoplasms are characterized by the proliferation of perivascular epithelioid cells (PECs), which are distinctive cells with an epithelioid appearance and a close association with blood vessel walls.

PEComas can occur in various organs, such as the kidney, liver, lung, pancreas, and gastrointestinal tract, but they most commonly involve the uterus. The World Health Organization (WHO) recognizes three main types of PEComas: epithelioid angiomyolipoma, clear cell "sugar" tumor, and lymphangioleiomyomatosis (LAM).

PEComas exhibit a wide range of clinical behaviors, from benign to malignant. Malignant PEComas typically display features such as infiltrative growth, high cellularity, nuclear atypia, increased mitotic activity, and necrosis. The pathogenesis of PEComas is not well understood, but recent studies suggest that they may be related to the TSC1 or TSC2 gene mutations, which are also associated with tuberous sclerosis complex (TSC), a genetic disorder characterized by benign tumors in multiple organs.

Diagnosis of PEComas is based on histopathological examination and immunohistochemical staining. The typical immunophenotype of PECs includes positivity for both melanocytic markers (such as HMB-45 and Melan-A) and smooth muscle markers (such as actin and desmin).

Treatment options for PEComas depend on the tumor's location, size, and clinical behavior. Surgical resection is the primary treatment modality for localized, symptomatic, or malignant PEComas. In some cases, systemic therapy with mammalian target of rapamycin (mTOR) inhibitors may be considered, particularly in metastatic or recurrent tumors.

Dental enamel hypoplasia is a condition characterized by the deficiency or reduction in the thickness of the tooth's enamel surface. This results in the enamel being thin, weak, and prone to wear, fractures, and dental cavities. The appearance of teeth with enamel hypoplasia may be yellowish, brownish, or creamy white, and they can have pits, grooves, or bands of varying widths and shapes.

Enamel hypoplasia can occur due to various factors, including genetics, premature birth, low birth weight, malnutrition, infections during childhood (such as measles or chickenpox), trauma, exposure to environmental toxins, and certain medical conditions that affect enamel formation.

The condition is usually diagnosed through a dental examination, where the dentist can observe and assess the appearance and structure of the teeth. Treatment options depend on the severity of the hypoplasia and may include fluoride treatments, sealants, fillings, crowns, or extractions in severe cases. Preventive measures such as maintaining good oral hygiene, a balanced diet, and regular dental check-ups can help reduce the risk of developing enamel hypoplasia.

Genetic skin diseases are a group of disorders caused by mutations or alterations in the genetic material (DNA), which can be inherited from one or both parents. These mutations affect the structure, function, or development of the skin and can lead to various conditions with different symptoms, severity, and prognosis.

Some examples of genetic skin diseases include:

1. Epidermolysis Bullosa (EB): A group of disorders characterized by fragile skin and mucous membranes that blister and tear easily, leading to painful sores and wounds. There are several types of EB, each caused by mutations in different genes involved in anchoring the epidermis to the dermis.
2. Ichthyosis: A family of genetic disorders characterized by dry, thickened, scaly, or rough skin. The severity and symptoms can vary widely, depending on the specific type and underlying genetic cause.
3. Neurofibromatosis: A group of conditions caused by mutations in the NF1 gene, which regulates cell growth and division. The most common types, NF1 and NF2, are characterized by the development of benign tumors called neurofibromas on the skin and nerves, as well as other symptoms affecting various organs and systems.
4. Tuberous Sclerosis Complex (TSC): A genetic disorder caused by mutations in the TSC1 or TSC2 genes, which control cell growth and division. TSC is characterized by the development of benign tumors in multiple organs, including the skin, brain, heart, kidneys, and lungs.
5. Xeroderma Pigmentosum (XP): A rare genetic disorder caused by mutations in genes responsible for repairing DNA damage from ultraviolet (UV) radiation. People with XP are extremely sensitive to sunlight and have a high risk of developing skin cancer and other complications.
6. Incontinentia Pigmenti (IP): A genetic disorder that affects the development and growth of skin, hair, nails, teeth, and eyes. IP is caused by mutations in the IKBKG gene and primarily affects females.
7. Darier's Disease: An inherited skin disorder characterized by greasy, crusted, keratotic papules and plaques, usually located on the trunk, scalp, and seborrheic areas of the body. Darier's disease is caused by mutations in the ATP2A2 gene.

These are just a few examples of genetic skin disorders. There are many more, each with its unique set of symptoms, causes, and treatments. If you or someone you know has a genetic skin disorder, it is essential to consult with a dermatologist or other healthcare professional for proper diagnosis and treatment.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

Brain diseases, also known as neurological disorders, refer to a wide range of conditions that affect the brain and nervous system. These diseases can be caused by various factors such as genetics, infections, injuries, degeneration, or structural abnormalities. They can affect different parts of the brain, leading to a variety of symptoms and complications.

Some examples of brain diseases include:

1. Alzheimer's disease - a progressive degenerative disorder that affects memory and cognitive function.
2. Parkinson's disease - a movement disorder characterized by tremors, stiffness, and difficulty with coordination and balance.
3. Multiple sclerosis - a chronic autoimmune disease that affects the nervous system and can cause a range of symptoms such as vision loss, muscle weakness, and cognitive impairment.
4. Epilepsy - a neurological disorder characterized by recurrent seizures.
5. Brain tumors - abnormal growths in the brain that can be benign or malignant.
6. Stroke - a sudden interruption of blood flow to the brain, which can cause paralysis, speech difficulties, and other neurological symptoms.
7. Meningitis - an infection of the membranes surrounding the brain and spinal cord.
8. Encephalitis - an inflammation of the brain that can be caused by viruses, bacteria, or autoimmune disorders.
9. Huntington's disease - a genetic disorder that affects muscle coordination, cognitive function, and mental health.
10. Migraine - a neurological condition characterized by severe headaches, often accompanied by nausea, vomiting, and sensitivity to light and sound.

Brain diseases can range from mild to severe and may be treatable or incurable. They can affect people of all ages and backgrounds, and early diagnosis and treatment are essential for improving outcomes and quality of life.

Encephalomalacia is a medical term that refers to the softening and degeneration of brain tissue. It is typically caused by an injury, infection, or lack of oxygen supply to the brain. This condition can lead to various neurological symptoms depending on the location and extent of the damage in the brain. Encephalomalacia may result in cognitive impairments, motor function loss, speech difficulties, and other long-term disabilities. Treatment options vary based on the underlying cause and severity of the condition but often include rehabilitation therapies to help manage symptoms and improve quality of life.

X-ray computed tomography (CT or CAT scan) is a medical imaging method that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional (tomographic) images (virtual "slices") of the body. These cross-sectional images can then be used to display detailed internal views of organs, bones, and soft tissues in the body.

The term "computed tomography" is used instead of "CT scan" or "CAT scan" because the machines take a series of X-ray measurements from different angles around the body and then use a computer to process these data to create detailed images of internal structures within the body.

CT scanning is a noninvasive, painless medical test that helps physicians diagnose and treat medical conditions. CT imaging provides detailed information about many types of tissue including lung, bone, soft tissue and blood vessels. CT examinations can be performed on every part of the body for a variety of reasons including diagnosis, surgical planning, and monitoring of therapeutic responses.

In computed tomography (CT), an X-ray source and detector rotate around the patient, measuring the X-ray attenuation at many different angles. A computer uses this data to construct a cross-sectional image by the process of reconstruction. This technique is called "tomography". The term "computed" refers to the use of a computer to reconstruct the images.

CT has become an important tool in medical imaging and diagnosis, allowing radiologists and other physicians to view detailed internal images of the body. It can help identify many different medical conditions including cancer, heart disease, lung nodules, liver tumors, and internal injuries from trauma. CT is also commonly used for guiding biopsies and other minimally invasive procedures.

In summary, X-ray computed tomography (CT or CAT scan) is a medical imaging technique that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional images of the body. It provides detailed internal views of organs, bones, and soft tissues in the body, allowing physicians to diagnose and treat medical conditions.

Chylothorax is a medical condition characterized by the accumulation of lymphatic fluid called chyle in the pleural space, which is the space between the lungs and the chest wall. Chyle is a milky-white fluid that contains nutrients, electrolytes, and immune cells, and it is normally transported through the thoracic duct to the bloodstream.

Chylothorax can occur due to various reasons, such as trauma, surgery, tumors, or congenital abnormalities that disrupt the normal flow of chyle. As a result, chyle leaks into the pleural space, causing symptoms such as cough, chest pain, difficulty breathing, and fever.

The diagnosis of chylothorax is usually made through imaging studies such as chest X-ray or CT scan, and confirmed by analyzing the fluid for the presence of chylomicrons, which are lipid particles found in chyle. The treatment options for chylothorax include dietary modifications, such as a low-fat diet with medium-chain triglycerides, chest tube drainage, and surgical interventions such as thoracic duct ligation or pleurodesis.

Tuberous sclerosis complex is diagnosed with clinical and genetic tests. There are many different mutations in the TSC1 and ... Tuberous sclerosis complex (TSC) is a rare multisystem autosomal dominant genetic disease that causes non-cancerous tumours to ... Tuberous sclerosis complex affects multiple organ systems so a multidisciplinary team of medical professionals is required.[ ... The disease is often abbreviated to tuberous sclerosis, which refers to the hard swellings in the brains of patients, first ...
Tuberous sclerosis is a genetic disorder that affects the skin, brain/nervous system, kidneys, heart, and lungs. The condition ... Tuberous sclerosis is a genetic disorder that affects the skin, brain/nervous system, kidneys, heart, and lungs. The condition ... Tuberous sclerosis fact sheet. NIH publication 07-1846. www.ninds.nih.gov/tuberous-sclerosis-fact-sheet. Updated March 2020. ... Sometimes when a child is born with severe tuberous sclerosis, one of the parents is found to have had a mild case of tuberous ...
Tuberous sclerosis complex (TSC) is a genetic disorder affecting cellular differentiation, proliferation, and migration early ... encoded search term (Tuberous Sclerosis) and Tuberous Sclerosis What to Read Next on Medscape ... Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex ... Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex ...
The Carol and James Herscot Center for Tuberous Sclerosis Complex raises awareness and provides education for people living ... with Tuberous Sclerosis Complex, their families, providers and others. ... Herscot Center for Tuberous Sclerosis. The Carol and James Herscot Center for Tuberous Sclerosis Complex raises awareness and ... Tuberous Sclerosis Complex Glossary. Explanations of common terms youll encounter when learning about TSC. ...
Formed in 1974 by four mothers, the Tuberous Sclerosis Alliance is dedicated to finding a cure for Tuberous Sclerosis Complex ( ... It is our pleasure to welcome you to tuberous sclerosis complex (TSC) week at the ATS. TSC is a rare genetic disorder that can ... With our PAR partner, the Tuberous Sclerosis Alliance, we aim to increase awareness of TSC. We hope to provide resources for ...
About Tuberous Sclerosis Canada Sclerose Tubereuse. The Tuberous Sclerosis Canada Sclerose Tubereuse (TSCST) is a non-profit ... Established in 1990, TSC facilitates a self-help network in which families affected by tuberous sclerosis support one another ... organization dedicated to raising public awareness of tuberous sclerosis complex (TSC); encouraging mutual support between ...
Tuberous sclerosis complex. Disease definition A rare neurocutaneous disorder characterized by multisystem hamartomas, most ... Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis is seen in up to 5% of patients presenting with TSC ... SEGA affects 10 to 20% of tuberous sclerosis complex (TSC) patients, almost exclusively children and young adults. Early-onset ...
Tuberous sclerosis 101 Tuberous sclerosis, also called tuberous sclerosis complex (TSC), is a rare, multi-system genetic ...
The UCLA Tuberous Sclerosis Complex (TSC) Program is one of the largest TSC programs in the Western United States. The program ... Our clinic is a Tuberous Sclerosis Alliance-designated clinic. The clinic focuses on diagnostic and ongoing assessments ... includes a multidisciplinary approach to clinical care for children with tuberous sclerosis complex, a newly developed adult ...
Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035.. 8. Northrup H, Krueger DA. Tuberous sclerosis complex ... Neurocutaneous Disorders: Tuberous Sclerosis Complex and Sturge-Weber Syndrome. Valerie Williams, RPh. Consultant Pharmacist. ... Tuberous sclerosis complex. An Bras Dermatol. 2012;87(2):184-196.. 7. Henske EP, Józwiak S, Kingswood JC, et al. ... Tuberous sclerosis complex: review based on new diagnostic criteria. An Bras Dermatol. 2018;93(3):323-331.. 4. National ...
The Tuberous Sclerosis Association support individuals and families affected by TSC. Our dedicated advisers and active ...
About Facial Angiofibroma Associated with Tuberous Sclerosis Complex Tuberous sclerosis complex (TSC) is an autosomal dominant ... HYFTOR™ (sirolimus topical gel) 0.2% is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis ... the first FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis, is now available in the US ... is the first and only topical medication approved by the FDA to treat facial angiofibroma associated with tuberous sclerosis in ...
The value of cortico-cortical evoked potentials (CCEP) was assessed in epileptogenic tuber localization for tuberous sclerosis ... Tuberous sclerosis complex (TSC) presents multiple cortical tubers in brain, and it is still difficulty to localize the ... Patients with tuberous sclerosis complex (TSC) present multiple cortical tubers in the brain, which are responsible for ... Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex ...
Tuberous Sclerosis - Learn about the causes, symptoms, diagnosis & treatment from the Merck Manuals - Medical Consumer Version. ... What is tuberous sclerosis? Tuberous sclerosis is a rare genetic disorder What is a genetic disorder? Your genes are the ... What causes tuberous sclerosis? Tuberous sclerosis is caused by an abnormal gene Genes and Chromosomes Your genes are the ... How do doctors know my baby has tuberous sclerosis? Doctors may suspect tuberous sclerosis if your baby has seizures and ...
... is the only organisation in Australia supporting people living with Tuberous Sclerosis Complex (TSC). ... TSA (Tuberous Sclerosis Australia) is Australias only charitable organisation supporting people with TSC (Tuberous Sclerosis ... Tuberous Sclerosis Australia Inc. is an incorporated association under New South Wales law. You can download and read our ... TSA (Tuberous Sclerosis Australia). 18 Central Road. Beverly Hills NSW 2209. Australia. ...
Tuberous sclerosis complex (TSC) is a rare disorder of tissue growth and differentiation, characterized by benign hamartomas in ... "Localization of the Epileptogenic Foci in Tuberous Sclerosis Complex: A Pediatric Case Report." Frontiers in Human Neuroscience ... Localization of the Epileptogenic Foci in Tuberous Sclerosis Complex: A Pediatric Case Report. ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
Tuberous sclerosis is a neurological disorder that can cause growths and tumors to develop inside vital organs. We specialize ... What is tuberous sclerosis? Tuberous sclerosis is a neurological disorder that can cause growths (called tubers) and tumors to ... Tuberous sclerosis is caused by a genetic mutation that either is inherited from a parent or acquired during development. A ... Some individuals with tuberous sclerosis experience developmental delays, mental retardation and/or seizures. Other individuals ...
Tuberous Sclerosis Australia Inc. is an incorporated association under New South Wales law. You can download and read our ... TSA (Tuberous Sclerosis Australia). 18 Central Road. Beverly Hills NSW 2209. Australia. ... Disclaimer: The information on this website is intended to provide basic information about Tuberous Sclerosis Complex (TSC). It ...
Krueger DA and Northrup H; International Tuberous Sclerosis Complex Consensus Group, . Tuberous sclerosis complex surveillance ... Northrup H and Krueger DA; International Tuberous Sclerosis Complex Consensus Group, . Tuberous sclerosis complex diagnostic ... Zhang Y, Gan J, Pu Z, Xu Mm, Wang LF, Li YH and Liu ZG: TSC1 R509X mutation in a chinese family with tuberous sclerosis complex ... Xue G, Han X, Ren S and Yue X: An Analysis of 11 Cases of Tuberous Sclerosis from Three Genealogies. Chin J Neuroimmunol and ...
UCSFs one-stop medical home for patients with tuberous sclerosis complex, providing medical, developmental and psychological ... The Tuberous Sclerosis Alliance has recognized our center since 2004 for its comprehensive care. ... The Jack & Julia Tuberous Sclerosis Complex (TSC) Center offers personalized medical, developmental and psychological care to ...
In turn, tuberous sclerosis (TSC) is characterized by autosomal dominant transmission and the inactivation of the TSC1 and/or ... Association of Down syndrome and tuberous sclerosis and their similarities in m-TOR pathway overactivation. About a case ... The association between Down syndrome and Tuberous sclerosis (DS/TSC) has very rarely been described. These two entities ... A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits. ...
Cognition, DTI, Epilepsy, Radial migration lines, Tuberous sclerosis complex Persistent URL doi.org/10.1007/s00234-013-1184-3, ... The neuroanatomical phenotype of tuberous sclerosis complex: Focus on radial migration lines. Publication. Publication. ... to the neuroanatomical and neurocognitive phenotype of tuberous sclerosis complex (TSC) is unclear. The aim of this study was ...
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease that affects multiple organ systems including the ... Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex ... Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis ... Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis. . Am J Respir Cell ...
The Consortium proposes to characterize the natural history of tuberous sclerosis complex TSC through development of an ... A Consortium was formed in July 2002 by the Tuberous Sclerosis Alliance TSA and tuberous sclerosis TS clinic personnel ... A Consortium was formed in July 2002 by the Tuberous Sclerosis Alliance TSA and tuberous sclerosis TS clinic personnel ... The Consortium proposes to characterize the natural history of tuberous sclerosis complex TSC through development of an ...
The Child Neurology Knowledge Environment and Official Website of the International Child Neurology Association.
... mutations in which cause tuberous sclerosis complex, is needed for budding nerve fibers to find their proper targets in the ... Tuberous sclerosis linked to brain cell migration. by Kelly Rae Chi / 8 February 2010 ... Tuberous sclerosis complex, or TSC, is a rare disorder characterized by the presence of benign tumors throughout the body, ... The TSC2 gene, mutations in which cause tuberous sclerosis complex, is needed for budding nerve fibers to find their proper ...
Tag: tuberous sclerosis. Illinois ag student seeks kidney donor. - December 17, 2021 Lance Moritz has known for most of his ... Born with tuberous sclerosis, which causes benign tumors to grow on organs, the 19-year-old who farms… ...
A description of Tuberous Sclerosis Complex with information on symptoms, causes and treatment. ... Tuberous Sclerosis Association UK. Tel: 0808 801 0700. Email: support@tuberous-sclerosis.org. Website: tuberous-sclerosis.org ... Tuberous Sclerosis Complex. Also known as: Tuberous Sclerosis. If your child is affected by a medical condition or disability ... Please see below for reliable medical information on Tuberous Sclerosis Complex produced by alternative providers. ...
  • Tuberous sclerosis complex (TSC) is a rare multisystem autosomal dominant genetic disease that causes non-cancerous tumours to grow in the brain and on other vital organs such as the kidneys, heart, liver, eyes, lungs and skin. (wikipedia.org)
  • Tuberous sclerosis complex (TSC) is a genetic disorder affecting cellular differentiation, proliferation, and migration early in development, resulting in a variety of hamartomatous lesions that may affect virtually every organ system of the body. (medscape.com)
  • Facial angiofibromas in a young man with tuberous sclerosis complex. (medscape.com)
  • Read about how Massachusetts General Hospital neurologists are working to reduce and eliminate the devastating effects of Tuberous Sclerosis Complex (TSC). (massgeneral.org)
  • It is our pleasure to welcome you to tuberous sclerosis complex (TSC) week at the ATS. (thoracic.org)
  • Formed in 1974 by four mothers, the Tuberous Sclerosis Alliance is dedicated to finding a cure for Tuberous Sclerosis Complex (TSC) while improving the lives of those affected. (thoracic.org)
  • Tuberous sclerosis (also referred to as tuberous sclerosis complex or TSC) is a relatively rare genetic disorder that causes tumors to form in various organs, including the brain, eyes, heart, kidney, skin and lungs. (childrensnational.org)
  • SEGA affects 10 to 20% of tuberous sclerosis complex (TSC) patients, almost exclusively children and young adults. (orpha.net)
  • The UCLA Tuberous Sclerosis Complex (TSC) Program is one of the largest TSC programs in the Western United States. (uclahealth.org)
  • The program includes a multidisciplinary approach to clinical care for children with tuberous sclerosis complex, a newly developed adult TSC neurology clinic, and many clinical research studies and clinical trials to advance knowledge and improve care for this rare genetic condition. (uclahealth.org)
  • Tuberous sclerosis complex (TSC) and Sturge-Weber syndrome (SWS) are prototypical neurocutaneous disorders. (uspharmacist.com)
  • Tuberous sclerosis complex (TSC) and Sturge-Weber syndrome (SWS) are prototypical neurocutaneous disorders in which genetic mutations in pathways regulating cell growth cause developmental dysfunction of the brain, skin, and other organs. (uspharmacist.com)
  • Tuberous sclerosis complex (TSC) is an autosomal dominant genetic rare disease that causes benign tumors to grow throughout the body. (prnewswire.com)
  • Patients with tuberous sclerosis complex (TSC) present multiple cortical tubers in the brain, which are responsible for epilepsy. (frontiersin.org)
  • Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome with TSC-1/TSC-2 gene mutations ( 1 - 3 ). (frontiersin.org)
  • These patches appear on many people who have tuberous sclerosis complex. (merckmanuals.com)
  • This photo shows red bumps consisting of blood vessels and fibrous tissue (angiofibromas) across the middle of the face of a person with tuberous sclerosis complex. (merckmanuals.com)
  • This photo shows small fleshy bumps (fibromas) that grow around and under the toenails and fingernails (Koenen tumors) in people who have tuberous sclerosis complex. (merckmanuals.com)
  • TSA (Tuberous Sclerosis Australia) is Australia's only charitable organisation supporting people with TSC (Tuberous Sclerosis Complex). (tsa.org.au)
  • Disclaimer: The information on this website is intended to provide basic information about Tuberous Sclerosis Complex (TSC). (tsa.org.au)
  • Tuberous sclerosis complex (TSC) is a rare disorder of tissue growth and differentiation, characterized by benign hamartomas in the brain and other organs. (harvard.edu)
  • Tuberous sclerosis complex‑associated renal angiomyolipoma (TSC‑RAML) confers a high risk of bleeding and even mortality. (spandidos-publications.com)
  • Tuberous sclerosis complex (TSC), an autosomal dominant disorder of multiple organ systems involving the brain, lung, kidney, skin and other organs ( 1 ), presents with a great variety of clinical manifestations ( 2 , 3 ). (spandidos-publications.com)
  • The Jack & Julia Tuberous Sclerosis Complex (TSC) Center offers personalized medical, developmental and psychological care to children as well as adults with this genetic disorder. (ucsfbenioffchildrens.org)
  • Introduction: The contribution of radial migration lines (RMLs) to the neuroanatomical and neurocognitive phenotype of tuberous sclerosis complex (TSC) is unclear. (eur.nl)
  • The Consortium proposes to characterize the natural history of tuberous sclerosis complex TSC through development of an internet-based DB to collect comprehensive data on individuals with TSC. (dtic.mil)
  • The director of the Tuberous Sclerosis Clinic at Cincinnati Children's discussed the neurodevelopmental impacts delaying seizures could lead to in tuberous sclerosis complex. (neurologylive.com)
  • Although there is no cure for tuberous sclerosis complex (TSC), there are a handful of treatments available to treat the symptoms. (neurologylive.com)
  • Despite considerable progress in the last few years, the neurobiologic basis of autism in tuberous sclerosis complex is still largely unknown and its clinical management represents a major challenge for child neurologists. (aston.ac.uk)
  • Please see below for reliable medical information on Tuberous Sclerosis Complex produced by alternative providers. (contact.org.uk)
  • It provides information and support to anyone affected by Tuberous Sclerosis Complex. (contact.org.uk)
  • Tuberous sclerosis complex is a genetic disease that can be inherited from one parent with TSC or can result from a spontaneous genetic mutation. (digitaltruthexplained.com)
  • Tuberous sclerosis, also known as tuberous sclerosis complex, is a rare genetic condition that causes mainly non-cancerous (benign) tumours to develop in different parts of the body. (digitaltruthexplained.com)
  • The program is made possible through the support of Bcureful, a 501(c)3 patient organization devoted to advancing research toward the cure for Tuberous Sclerosis Complex, as well as raising public awareness of the disorder and helping to bring expert medical care and support to people where they need it. (digitaltruthexplained.com)
  • Cannabidiol (CBD) treatment in patients with seizures associated with tuberous sclerosis complex: A randomized, double-blind, placebo-controlled phase 3 … Rapamycin (sirolimus) may be useful in tuberous sclerosis treatment. (digitaltruthexplained.com)
  • Purpose: The purpose of this study was to evaluate the long-term results of eight cases diagnosed with tuberous sclerosis complex (TSC) and receiving rapamycin therapy because of epileptic seizures and/or accompanying TSC findings. (digitaltruthexplained.com)
  • Step Forward to Cure TSC® is the TS Alliance's largest national fundraising event, organized by local volunteers and families who are affected by tuberous sclerosis complex (TSC) in more than 30 communities across the United States. (digitaltruthexplained.com)
  • Neurological and you can neuropsychiatric aspects of tuberous sclerosis complex. (miner.exchange)
  • Tuberous sclerosis (TS), also known as tuberous sclerosis complex, is a rare genetic disorder that causes non-cancerous tumors to grow in various parts of the body. (totalcareaba.com)
  • Tuberous sclerosis complex is a rare genetic disorder that affects approximately 1 in 6,000 to 10,000 individuals worldwide. (totalcareaba.com)
  • Tuberous sclerosis, also known as tuberous sclerosis complex (TSC), is a rare genetic condition that causes non-malignant tumours to develop in organs such as brain, heart, eyes, skin, lungs and kidneys. (inspired4care.co.uk)
  • When Kristen Moore's son Jackson was first diagnosed with tuberous sclerosis complex (TSC), she decided to translate her emotions into action. (patientworthy.com)
  • According to a recent announcement, Epilepsy Research UK has announced a funding collaboration with the Tuberous Sclerosis Association which will support the investigation of tuberous sclerosis complex (TSC)-associated epilepsy. (patientworthy.com)
  • Tuberous sclerosis complex (TSC) is classified as a rare genetic disorder that causes typically benign tumors in the brain, skin, heart, kidneys, or lungs. (patientworthy.com)
  • A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce a particular kind of brain tumor in patients with tuberous sclerosis complex (TSC) - a genetic disease that causes tumors to grow on vital organs. (parenthub.com.au)
  • Tuberous sclerosis complex (TSC) is an autosomal dominant syndrome that causes tumor formation in multiple organs. (wustl.edu)
  • High glucose concentrations mask cellular phenotypes in a stem cell model of tuberous sclerosis complex. (ox.ac.uk)
  • Tuberous sclerosis complex (TSC) is a neurodevelopmental disorder caused by deletions in the TSC1 or TSC2 genes that is associated with epilepsy in up to 90% of patients. (ox.ac.uk)
  • Tuberous Sclerosis Complex-1 (TSC1) contributes to selective neuronal vulnerability in Alzheimer's Disease. (ox.ac.uk)
  • Successful treatment of arrhythmia-induced cardiomyopathy in an infant with tuberous sclerosis complex. (bvsalud.org)
  • Tuberous sclerosis complex (TSC) is an autosomal-dominant tumor suppressor gene syndrome that is characterized by the development of distinctive benign tumors and malformations in multiple organ systems (N Eng J Med 3551345-1356, 2006). (bvsalud.org)
  • Some individuals with tuberous sclerosis experience developmental delays, mental retardation and/or seizures. (uchicagomedicine.org)
  • Our team provides personalized, compassionate care for individuals with tuberous sclerosis. (uchicagomedicine.org)
  • Ongoing research is being conducted to further understand this connection and develop effective treatments for individuals with tuberous sclerosis and ASD. (totalcareaba.com)
  • The central nervous system is frequently involved in individuals with tuberous sclerosis. (nikoismusic.com)
  • Tuberous sclerosis is a neurological disorder that can cause growths (called tubers) and tumors to develop inside vital organs, including the brain, kidneys, lungs, heart and skin. (uchicagomedicine.org)
  • SEGAs are slow-growing, benign brain tumors that occur in up to 20% of patients with tuberous sclerosis , a genetic disorder that affects about 25,000 to 40,000 people in the United States. (medscape.com)
  • Cite this: FDA Approves First Therapy for Tuberous Sclerosis Tumors - Medscape - Nov 02, 2010. (medscape.com)
  • This study is investigating what causes multiple skin tumors to develop in people with tuberous sclerosis. (nih.gov)
  • What are the symptoms of tuberous sclerosis? (merckmanuals.com)
  • Although there currently is no cure for tuberous sclerosis, early intervention and comprehensive care can help patients manage their symptoms. (uchicagomedicine.org)
  • In addition to treating individuals diagnosed during infancy, our team sees adult patients who have recently started experiencing signs and symptoms of tuberous sclerosis. (uchicagomedicine.org)
  • Kothare SV, Singh K, Chalifoux JR, Staley BA, Weiner HL, Menzer K, Devinsky O. Severity out of symptoms in the tuberous sclerosis cutting-edge in terms of genotype. (miner.exchange)
  • Medications to control the seizures (anti-epileptic drugs) will usually be tried first, although they're not always effective for people with tuberous sclerosis. (digitaltruthexplained.com)
  • The fresh spectral range of mutations inside TSC1 and you may TSC2 in females having tuberous sclerosis and lymphangiomyomatosis. (miner.exchange)
  • One specific gene that has been linked to both tuberous sclerosis and ASD is the TSC1 gene. (totalcareaba.com)
  • The disease is often abbreviated to tuberous sclerosis, which refers to the hard swellings in the brains of patients, first described by French neurologist Désiré-Magloire Bourneville in 1880. (wikipedia.org)
  • While tuberous sclerosis is a lifelong condition that requires ongoing management, many patients enjoy a fulfilling, active life when they receive proper treatment. (childrensnational.org)
  • Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis is seen in up to 5% of patients presenting with TSC and should be excluded. (orpha.net)
  • The University of Chicago Medicine is home to a unique tuberous sclerosis program, where pediatric neurologists and neurosurgeons diagnose and manage this condition in patients of all ages. (uchicagomedicine.org)
  • By including adults and children in one comprehensive clinic, our specialists are able to provide continuity of care as patients born with tuberous sclerosis transition into adulthood. (uchicagomedicine.org)
  • We provide personalized care for patients in all stages of life and with varying courses of tuberous sclerosis. (uchicagomedicine.org)
  • For additional information and resources, contact the Tuberous Sclerosis Alliance at www.tsalliance.org . (medlineplus.gov)
  • With our PAR partner, the Tuberous Sclerosis Alliance, we aim to increase awareness of TSC. (thoracic.org)
  • Children's National has one of the few tuberous sclerosis programs recognized by the Tuberous Sclerosis Alliance . (childrensnational.org)
  • Our clinic is a Tuberous Sclerosis Alliance-designated clinic. (uclahealth.org)
  • To learn more about TSC, please visit Tuberous Sclerosis Alliance . (texaschildrens.org)
  • The Tuberous Sclerosis Alliance has recognized our center since 2004 for its comprehensive care. (ucsfbenioffchildrens.org)
  • A Consortium was formed in July 2002 by the Tuberous Sclerosis Alliance TSA and tuberous sclerosis TS clinic personnel nationwide to begin discussions of natural history studies and development of a comprehensive clinical database DB to be used for both research and clinical purposes. (dtic.mil)
  • In fact, studies have shown that up to 60% of people with tuberous sclerosis can also have autism spectrum disorder (ASD). (totalcareaba.com)
  • Tuberous sclerosis (TS) is an autosomal dominant disorder. (uhhospitals.org)
  • The multidisciplinary clinic team follows more than 800 children and adults with tuberous sclerosis and manages every aspect of the disorder. (parenthub.com.au)
  • HYFTOR is the first and only topical medication approved by the FDA to treat facial angiofibroma associated with tuberous sclerosis in adults and children 6 years of age and older and received Orphan Drug status for this indication. (prnewswire.com)
  • HYFTOR™ (sirolimus topical gel) 0.2% is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and children 6 years of age and older. (prnewswire.com)
  • Genetic counseling also can determine if tuberous sclerosis affects other members of the patient's family. (uchicagomedicine.org)
  • Tuberous sclerosis also affects many other organs in the body. (uhhospitals.org)
  • Association of Down syndrome and tuberous sclerosis and their similarities in m-TOR pathway overactivation. (elsevier.es)
  • The association between Down syndrome and Tuberous sclerosis (DS/TSC) has very rarely been described. (elsevier.es)
  • A congenital condition, tuberous sclerosis is present at birth and often diagnosed during infancy, but also can remain undiagnosed in individuals with mild forms. (uchicagomedicine.org)
  • Incidence of autism associated with Tuberous Sclerosis may be significantly higher than the rates of cardiac and renal abnormalities, for which screening is routinely conducted in this population. (aston.ac.uk)
  • Do you have tuberous sclerosis and want to help researchers better understand the disease? (nih.gov)
  • Tuberous sclerosis is caused by a genetic mutation that either is inherited from a parent or acquired during development. (uchicagomedicine.org)
  • Genetic testing to determine if the mutation associated with tuberous sclerosis is present. (uchicagomedicine.org)
  • A novel missense mutation in the GTPase triggering proteins homology region away from TSC2 in 2 higher family members having tuberous sclerosis cutting-edge. (miner.exchange)
  • Hopefully, early diagnosis of autism will allow for earlier treatment and the potential for better outcome for children with Tuberous Sclerosis. (aston.ac.uk)
  • Children with mild tuberous sclerosis most often do well. (medlineplus.gov)
  • At Children's National Hospital, we are dedicated to providing advanced, compassionate and individualized care to children with tuberous sclerosis. (childrensnational.org)
  • Most people with tuberous sclerosis have patches of light-colored skin, or they may develop small, harmless areas of thickened, smooth skin or reddish bumps under or around the nails. (nikoismusic.com)
  • Tuberous Sclerosis Australia Inc. is an incorporated association under New South Wales law. (tsa.org.au)
  • Sometimes when a child is born with severe tuberous sclerosis, one of the parents is found to have had a mild case of tuberous sclerosis that was not diagnosed. (medlineplus.gov)
  • 3 The name tuberous sclerosis comes from the characteristic tuber or potato-like nodules in the brain, which calcify with age and become hard or sclerotic. (uspharmacist.com)

No images available that match "tuberous sclerosis"